Pre-made Bamlanivimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bamlanivimab (INN, codenamed LY-CoV555) is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The drug was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and 950,000 doses have been bought by the US government as of December 2020. In April 2021, the EUA was revoked.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-045-1mg	1mg	3090
GMP-Bios-ab-045-10mg	10mg	Inquiry
GMP-Bios-ab-045-100mg	100mg	Inquiry
GMP-Bios-ab-045-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody
INN Name	Bamlanivimab
Target	SARS-CoV-2 Spike
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	7l3n:DE/7kmg:AB:DE
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases
Conditions Approved	COVID-19
Conditions Active	na
Conditions Discontinued	na
Development Tech	Baiting from convalescent human B-cells